[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100444435":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":48,"centralContacts":52,"locations":58,"responsibleParty":77,"collaborators":35,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":35,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":103,"overallStatus":105,"whyStopped":35,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"University of California, Los Angeles","OTHER",[8,14,20,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR","Oral placebo; sesame and MCT oil",[13],"Drug: Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"20 mg THC","EXPERIMENTAL","THC suspended in sesame oil",[19],"Drug: THC",{"label":21,"type":16,"description":22,"interventionNames":23},"20 mg CBD","CBD suspended in MCT oil",[24],"Drug: CBD",{"label":26,"type":16,"description":27,"interventionNames":28},"20 mg THC + 20 mg CBD","THC and CBD in sesame and MCT oil",[29],"Drug: THC + CBD",[31,36,40,44],{"type":32,"name":9,"description":33,"armGroupLabels":34,"otherNames":35},"DRUG","Oral placebo",[9],null,{"type":32,"name":37,"description":38,"armGroupLabels":39,"otherNames":35},"THC","Oral THC (20 mg)",[15],{"type":32,"name":41,"description":42,"armGroupLabels":43,"otherNames":35},"CBD","Oral CBD (20 mg)",[21],{"type":32,"name":45,"description":46,"armGroupLabels":47,"otherNames":35},"THC + CBD","Oral THC (20 mg) + CBD (20 mg)",[26],[49],{"name":50,"affiliation":5,"role":51},"Ziva Cooper","PRINCIPAL_INVESTIGATOR",[53],{"name":54,"role":55,"phone":56,"phoneExt":35,"email":57},"Ziva Cooper, PhD","CONTACT","310-206-9942","zcooper@mednet.ucla.edu",[59],{"facility":5,"status":35,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"Los Angeles","California","90095","United States","US",{"type":66,"coordinates":67},"Point",[68,69],-118.24368,34.05223,{"lat":69,"lon":68},[72,73],{"name":54,"role":55,"phone":56,"phoneExt":35,"email":57},{"name":74,"role":55,"phone":75,"phoneExt":35,"email":76},"Vince Acebo","310-983-3417","vacebo@mednet.ucla.edu",{"type":51,"investigatorFullName":78,"investigatorTitle":79,"investigatorAffiliation":5,"oldNameTitle":35,"oldOrganization":35},"Ziva D. Cooper, PhD","Associate Professor","100444435","phase-1-evaluation-of-oral-thc-and-cbd-in-men-and-women-100444435",false,"NCT05067387","Evaluation of Oral THC and CBD in Men and Women","Evaluation of Oral THC and CBD in Oral Fluid, Pharmacokinetics, and Subjective and Neurocognitive Effects in Men and Women","O-TACOFS","Inclusion Criteria:\n\n* Male or non-pregnant and non-lactating females aged 21-55 years\n* Report weekly-monthly use of cannabis (≤1 day per week) over the past month prior to screening,\n* Not currently seeking treatment for their cannabis use\n* Have a Body Mass Index from 18.5 - 34kg\u002Fm2.\n* Able to perform all study procedures\n* Must be using a contraceptive (hormonal or barrier methods)\n\nExclusion Criteria:\n\n* Meeting DSM-V criteria for moderate to severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine\n* Any other Axis I disorder\n* Report using other illicit drugs in the prior 4 weeks, other than cannabis.\n* Current use of any medications that may affect study outcomes\n* If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process are not within the normal range and \u002F or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures.\n* Pregnancy is exclusionary due to the possible effects of the study medication on fetal development.\n* History of an allergic reaction or adverse reaction to cannabis is exclusionary.\n* History of respiratory illness or current respiratory illness\n* Currently enrolled in another research protocol\n* Not using a contraceptive method (hormonal or barrier methods)\n* The evaluating physician reviews all medical assessments along with medical history. Any disorders that might make cannabis administration hazardous are exclusionary.",true,"ALL","21 Years","55 Years",{"count":93,"type":94},22,"ESTIMATED","INTERVENTIONAL",[97],"PHASE1","The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.",[100,101,102],"Drug Abuse","Intoxication by Drug","Impairment",[37,41,104,102],"Intoxication","NOT_YET_RECRUITING","2026-06-09",{"date":108,"type":109},"2026-06-11","ACTUAL",{"date":111,"type":94},"2026-07-15",{"date":113,"type":94},"2028-06-15",{"name":5,"class":6},1]